I
Power Law company profile
Immunai
Biotech & Life Sciences · New York City, United States · Founded 2019 Unicorn
Global footprint
Where Immunai has talent and traffic
AI talent share
11.1%
of workforce is AI talent
(20 of 180 staff)
(20 of 180 staff)
Core AI116.11%
Other AI95%
Non-AI workforce16088.89%
Web traffic by country
7.1K
monthly visits
across markets
across markets
🇺🇸 United States76.1%
🇨🇦 Canada9.9%
🇨🇿 Czech Republic7%
🇯🇵 Japan5.6%
🇩🇪 Germany0%
Patent intelligence
$90k patent portfolio · 3 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$90k
<0.01% of valuation · 8688.9× smaller than top peer BioNTech ($780M)
3 active patent families
Where Immunai innovates
Molecular biologyMarker genePlasma lipidsHepatic lipidGene
Below peer median on Legal, Strategic, Market, Economic, Technology
Quality vs same-sector peers
Immunai on the five Patsnap quality dimensions
Immunai in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Immunai concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Immunai and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Immunai on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.